EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Sodium-glucose cotransporter 2 inhibitors in the treatment of heart failure patients: A systematic review and meta-analysis of cost-utility studies

Xinyue Zhang, Yanxia Zhang, Jiayu Wang, Zhijia Tang

Archives of Gerontology and Geriatrics · 2025

DOI: 10.1016/j.archger.2025.105809 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Archives of Gerontology and Geriatrics, 2025. Verfasst von Xinyue Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, PR China. Electronic address: 2221103004…. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Heart Failure. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 90 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) have shown promise in reducing cardiovascular mortality and hospitalization due to heart failure (HF), a significant global health issue. This study aims to evaluate the incremental net benefit (INB) of SGLT-2i in HF patients through a systematic review and meta-analysis of cost-utility studies. METHODS: We searched five databases from their inception until Aug 30, 2024, economic evolution studies reporting cost-effectiveness and cost-utility analyses comparing SGLT-2i combined with standard triple-therapy versus standard triple-therapy alone in HF patients were selected. INB as the primary outcome was calculated in monetary units adjusted for purchasing power parity in 2022 US dollars. RESULTS: This review included 46 studies, with 41 studies (55 comparisons) pooled into meta-analysis. Adding SGLT2is was cost-effective compared to standard triple-therapy alone, from both healthcare system perspective (INB, $4042.08; 95 % CI, $1758.70-$6325.46) and payer perspective (INB, $12,972.84; 95 % CI, $4711.5-$21,234.22). However, subgroup analyses showed non-significant economic benefit in HF patients with preserved ejection fraction (HFpEF) both from the healthcare system perspective (INB, -$639.32; 95 % CI, -$1850.09-$571.44) and the payer perspective (INB, $3611.07; 95 % CI, -$208.49-$7430.64). Additionally, HF patients from low- and middle-income countries did not show significant economic benefit from the payer perspective (INB, $55,645.70; 95 % CI, -$51,000.00-$160,000.00). CONCLUSIONS: The findings suggest that adding SGLT-2i is cost-effective compared to conventional standard triple-therapy alone, from both healthcare system and payer perspectives. Nevertheless, the economic benefits are limited in HFpEF and those from low- and middle-income countries. Further research is needed to explore the cost-effectiveness from a broader societal perspective.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsHeart FailureHumansCost-Benefit Analysis

Stichwörter der Autor:innen

Cost–effectivenessHealth economicsHeart failure (HF)Incremental net benefit (INB)Sodium–glucose cotransporter–2 inhibitors (SGLT–2i)

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, PR China. Electronic address: 22211030046@m.fudan.edu.cn.
  • Department of Pharmacy, Minhang Hospital, Fudan University, Shanghai, PR China. Electronic address: zhangyanxia@fudan.edu.cn.
  • Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, PR China. Electronic address: wangjiayu20@fudan.edu.cn.
  • Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, PR China; Shanghai Center for Adverse Drug and Medical Device Reaction Monitoring, Shanghai, PR China. Electro…

Zitieren

APA

Zhang, X., Zhang, Y., Wang, J., & Tang, Z. (2025). Sodium-glucose cotransporter 2 inhibitors in the treatment of heart failure patients: A systematic review and meta-analysis of cost-utility studies. Archives of Gerontology and Geriatrics. https://doi.org/10.1016/j.archger.2025.105809

Vancouver

Zhang X, Zhang Y, Wang J, Tang Z. Sodium-glucose cotransporter 2 inhibitors in the treatment of heart failure patients: A systematic review and meta-analysis of cost-utility studies. Archives of Gerontology and Geriatrics. 2025. doi:10.1016/j.archger.2025.105809

BibTeX
@article{Zhang2025,
  author = {Zhang, Xinyue and Zhang, Yanxia and Wang, Jiayu and Tang, Zhijia},
  title = {Sodium-glucose cotransporter 2 inhibitors in the treatment of heart failure patients: A systematic review and meta-analysis of cost-utility studies},
  journal = {Archives of Gerontology and Geriatrics},
  year = {2025},
  doi = {10.1016/j.archger.2025.105809}
}
Kostenlos starten →